NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

Valproic Acid Upregulates NKG2D Ligand Expression through an ERK-dependent Mechanism and Potentially Enhances NK Cell-mediated Lysis of Myeloma

(2015) Xiaosong Wu et al.   NEOPLASIA

Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance

(2014) D. Gotthardt et al.   BLOOD

Reactive Oxygen Species– and DNA Damage Response–Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1

(2014) Alessandra Soriani et al.   JOURNAL OF IMMUNOLOGY

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

(2014) N I Herath et al.   Blood Cancer Journal

Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells

(2013) N. Fiegler et al.   BLOOD

DNA repair pathways in human multiple myeloma

(2013) Claire Gourzones-Dmitriev et al.   CELL CYCLE

Inhibition of Glycogen Synthase Kinase-3 Increases NKG2D Ligand MICA Expression and Sensitivity to NK Cell-Mediated Cytotoxicity in Multiple Myeloma Cells: Role of STAT3

(2013) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells

(2013) J. Bae et al.   JOURNAL OF IMMUNOLOGY

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

Allogeneic hematopoietic stem cell transplantation for multiple myeloma

(2012) Guenther Koehne et al.   CURRENT OPINION IN ONCOLOGY

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

(2012) Britta Lamottke et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells

(2012) KOJI YAMANEGI et al.   ONCOLOGY REPORTS

Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation

(2012) H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib

(2012) T Ishii et al.   Blood Cancer Journal

Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression

(2011) Xiulong Xu et al.   BMC CANCER

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells

(2011) R. Bedel et al.   CANCER RESEARCH

Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2

(2011) S. Textor et al.   CANCER RESEARCH

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2

(2011) Hai Li et al.   CELL CYCLE

Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy

(2011) Kristijan Ramadan et al.   FEBS LETTERS

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer

(2011) Baocheng Huang et al.   JOURNAL OF IMMUNOTHERAPY

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression

(2011) Lucas E. Rossi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

(2011) B Mohty et al.   LEUKEMIA

SUMO in the mammalian response to DNA damage: Figure 1

(2010) Joanna R. Morris   BIOCHEMICAL SOCIETY TRANSACTIONS

Pharmaceutical inhibition of glycogen synthetase kinase-3  reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model

(2010) W. G. Gunn et al.   BLOOD

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death

(2010) Francesco Piazza et al.   BMC CANCER

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

(2010) J. N. Kyula et al.   CLINICAL CANCER RESEARCH

Glycogen synthase kinase 3: A point of convergence for the host inflammatory response

(2010) Huizhi Wang et al.   CYTOKINE

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells

(2010) Xiaoli Feng et al.   MOLECULAR IMMUNOLOGY

Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma

(2009) K. Kohga et al.   CANCER RESEARCH

Regulatory ubiquitylation in response to DNA double-strand breaks

(2009) Stephanie Panier et al.   DNA REPAIR

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

(2009) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity

(2009) X. Wang et al.   HAEMATOLOGICA

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

(2009) A M Vahdat et al.   LEUKEMIA

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

(2009) A Poggi et al.   LEUKEMIA

The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress

(2009) Joanna R. Morris et al.   NATURE

Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks

(2009) Yaron Galanty et al.   NATURE

Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine

(2008) Kai-Fu Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy

(2008) Jia Luo   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3

(2008) Eléonore Beurel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3

(2008) Ying Zhou et al.   LEUKEMIA & LYMPHOMA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA